Zoetis (ZTS) Projected to Post Quarterly Earnings on Tuesday

Zoetis (NYSE:ZTS) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect Zoetis to post earnings of $1.41 per share and revenue of $2.20 billion for the quarter. Zoetis has set its FY 2025 guidance at 6.000-6.100 EPS.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. On average, analysts expect Zoetis to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Zoetis Stock Up 0.2 %

ZTS opened at $153.78 on Tuesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The business has a 50 day moving average price of $158.84 and a 200 day moving average price of $168.07. The firm has a market cap of $68.61 billion, a P/E ratio of 28.11, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. Zoetis has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.30%. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of analyst reports. Morgan Stanley cut their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Barclays boosted their target price on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Piper Sandler raised their price objective on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Finally, Stifel Nicolaus cut their price target on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Monday, April 14th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $214.40.

Insider Transactions at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock valued at $312,254 in the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zoetis

An institutional investor recently raised its position in Zoetis stock. Brighton Jones LLC boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 180.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,629 shares of the company’s stock after purchasing an additional 2,978 shares during the quarter. Brighton Jones LLC’s holdings in Zoetis were worth $754,000 at the end of the most recent quarter. 92.80% of the stock is owned by institutional investors.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.